NZ756307A - Formulations of cannabinoids for the treatment of acne - Google Patents

Formulations of cannabinoids for the treatment of acne

Info

Publication number
NZ756307A
NZ756307A NZ756307A NZ75630718A NZ756307A NZ 756307 A NZ756307 A NZ 756307A NZ 756307 A NZ756307 A NZ 756307A NZ 75630718 A NZ75630718 A NZ 75630718A NZ 756307 A NZ756307 A NZ 756307A
Authority
NZ
New Zealand
Prior art keywords
cannabinoids
acne
formulations
treatment
cannabinoid
Prior art date
Application number
NZ756307A
Other languages
English (en)
Inventor
Eugene Cooper
Matthew Callahan
Original Assignee
Botanix Pharmaceuticals Ltd
Botanix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017900493A external-priority patent/AU2017900493A0/en
Application filed by Botanix Pharmaceuticals Ltd, Botanix Pharmaceuticals Inc filed Critical Botanix Pharmaceuticals Ltd
Priority claimed from PCT/AU2018/050045 external-priority patent/WO2018148786A1/en
Publication of NZ756307A publication Critical patent/NZ756307A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
NZ756307A 2017-02-15 2018-01-24 Formulations of cannabinoids for the treatment of acne NZ756307A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762459313P 2017-02-15 2017-02-15
AU2017900493A AU2017900493A0 (en) 2017-02-15 Formulations of Cannabinoids for the Treatment of Acne
PCT/AU2018/050045 WO2018148786A1 (en) 2017-02-15 2018-01-24 Formulations of cannabinoids for the treatment of acne

Publications (1)

Publication Number Publication Date
NZ756307A true NZ756307A (en) 2023-01-27

Family

ID=67766784

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ756307A NZ756307A (en) 2017-02-15 2018-01-24 Formulations of cannabinoids for the treatment of acne

Country Status (9)

Country Link
US (1) US20220323401A1 (enExample)
EP (1) EP3582770A4 (enExample)
JP (2) JP2020508992A (enExample)
CN (1) CN110769819A (enExample)
AU (1) AU2018221881B2 (enExample)
BR (1) BR112019017049A2 (enExample)
CA (1) CA3053503C (enExample)
IL (1) IL268728B2 (enExample)
NZ (1) NZ756307A (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018221881B2 (en) * 2017-02-15 2023-09-14 Botanix Pharmaceuticals Ltd Formulations of cannabinoids for the treatment of acne
EP4111193A4 (en) * 2020-02-25 2024-04-03 Advanced Animal Diagnostics, Inc. METHODS AND COMPOSITIONS FOR IDENTIFYING A SURVIVAL INDEX FOR AN ANIMAL
CN114073687A (zh) * 2020-08-21 2022-02-22 四川大学华西医院 大麻二酚在制备防治玫瑰痤疮的药物中的用途
CN113372196B (zh) * 2021-07-02 2022-09-30 江南大学 8,9-二氢大麻二酚及其合成方法与应用
JP7736306B2 (ja) * 2022-11-18 2025-09-09 株式会社ニューギン 遊技機
JP7736310B2 (ja) * 2022-11-18 2025-09-09 株式会社ニューギン 遊技機
JP7736309B2 (ja) * 2022-11-18 2025-09-09 株式会社ニューギン 遊技機
JP7736308B2 (ja) * 2022-11-18 2025-09-09 株式会社ニューギン 遊技機

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0104268D0 (en) * 2001-02-21 2001-04-11 Unilever Plc Antiperspirant or deodorant compositions
DE60228713D1 (de) * 2001-07-18 2008-10-16 Unilever Nv Zusammensetzungen für die behandlung von haaren und/oder kopfhaut
WO2008024408A2 (en) * 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Pharmaceutical formulations of cannabinoids for application to the skin and method of use
WO2009072007A2 (en) * 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
WO2010127033A1 (en) * 2009-04-28 2010-11-04 Alltranz Inc. Formulations of cannabidiol and methods of using the same
ES2541485T3 (es) * 2010-10-19 2015-07-21 Parenteral, A.S. Composición para el tratamiento de enfermedades inflamatorias, la cual comprende ácidos boswéllicos y cannabidiol
US8758826B2 (en) * 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
US20130184354A1 (en) * 2012-01-13 2013-07-18 Donna K. Jackson Silicone and Hylauronic Acid (HLA) Delivery Systems for Products by Sustainable Processes for Medical Uses Including Wound Management
NZ707855A (en) * 2012-11-06 2018-11-30 Rochal Ind Llc Delivery of biologically-active agents using volatile, hydrophobic solvents
WO2014116653A1 (en) * 2013-01-22 2014-07-31 Coty Inc. Topical formulations and methods for the use thereof
US20160022627A2 (en) * 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
BR112017018944A2 (en) * 2015-03-02 2018-05-15 Afgin Pharma, Llc method of treating a disease state or condition in humans with a carbinoid drug, and method of treating a disease state or condition in a mammal other than a human with carbinoid drug (s)
MA42268A (fr) * 2015-06-23 2018-05-02 Axim Biotechnologies Inc Compositions antimicrobiennes contenant des cannabinoïdes
AU2018221880B2 (en) * 2017-02-15 2023-08-17 Botanix Pharmaceuticals Ltd Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases
AU2018221881B2 (en) * 2017-02-15 2023-09-14 Botanix Pharmaceuticals Ltd Formulations of cannabinoids for the treatment of acne

Also Published As

Publication number Publication date
EP3582770A1 (en) 2019-12-25
CA3053503A1 (en) 2018-08-23
US20220323401A1 (en) 2022-10-13
EP3582770A4 (en) 2020-11-18
CA3053503C (en) 2024-04-23
AU2018221881A1 (en) 2019-09-05
JP2022185150A (ja) 2022-12-13
IL268728A (en) 2019-10-31
AU2018221881B2 (en) 2023-09-14
BR112019017049A2 (pt) 2020-04-14
CN110769819A (zh) 2020-02-07
IL268728B1 (en) 2024-05-01
JP2020508992A (ja) 2020-03-26
IL268728B2 (en) 2024-09-01

Similar Documents

Publication Publication Date Title
EP4193993A3 (en) Combinations of cannabinoids and n-acylethanolamines
PH12019502646A1 (en) Pyrazole magl inhibitors
IL258854A (en) Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
MX2021006035A (es) Formulaciones cannabinoides estables.
EP4272834A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
GB201411465D0 (en) Active pharmaceutical ingredient (api) comprising cannabinoids for use in the treatment of cancer
MX378273B (es) Compuestos activos hacia bromodominios.
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
MX2016012262A (es) Cenicriviroc para el tratamiento de fibrosis.
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
MX380252B (es) Crenezumab para usarse en el tratamiento de enfermedad de alzheimer.
SA519400913B1 (ar) تركيبة موضعية لتعزيز إلتئام الجروح
AU2015352158A8 (en) Medicaments for slowing Parkinson's Disease
IL268728A (en) Formulations of cannabinoids for the treatment of acne
DOP2018000034A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
MX383254B (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX392053B (es) Composiciones cosmeticas y metodo para tratar la piel
PH12020550532A1 (en) Agent for preventing or treating small intestinal injury induced by non-steroidal anti-inflammatory drug and proton pump inhibitor
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
MX381598B (es) Combinación farmacéutica que comprende un parvovirus y bevacizumab.
MX2019010218A (es) Derivados de pirazol como inhibidores de bromodominio.
MX2017010277A (es) Cenicriviroc para el tratamiento de la fibrosis.
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
BR112018076935A2 (pt) composição, medicamento e método para o tratamento da alopecia induzida por quimioterapia

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JAN 2025 BY WRAYS PTY LTD

Effective date: 20231127

LAPS Patent lapsed